Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Broader Epstein-Barr virus-specific T cell receptor repertoire in patients with multiple sclerosis.
Schneider-Hohendorf T, Gerdes LA, Pignolet B, Gittelman R, Ostkamp P, Rubelt F, Raposo C, Tackenberg B, Riepenhausen M, Janoschka C, Wünsch C, Bucciarelli F, Flierl-Hecht A, Beltrán E, Kümpfel T, Anslinger K, Gross CC, Chapman H, Kaplan I, Brassat D, Wekerle H, Kerschensteiner M, Klotz L, Lünemann JD, Hohlfeld R, Liblau R, Wiendl H, Schwab N. Schneider-Hohendorf T, et al. Among authors: riepenhausen m. J Exp Med. 2022 Nov 7;219(11):e20220650. doi: 10.1084/jem.20220650. Epub 2022 Sep 1. J Exp Med. 2022. PMID: 36048016 Free PMC article.
Alemtuzumab-induced immune phenotype and repertoire changes: implications for secondary autoimmunity.
Ruck T, Barman S, Schulte-Mecklenbeck A, Pfeuffer S, Steffen F, Nelke C, Schroeter CB, Willison A, Heming M, Müntefering T, Melzer N, Krämer J, Lindner M, Riepenhausen M, Gross CC, Klotz L, Bittner S, Muraro PA, Schneider-Hohendorf T, Schwab N, Meyer Zu Hörste G, Goebels N, Meuth SG, Wiendl H. Ruck T, et al. Among authors: riepenhausen m. Brain. 2022 Jun 3;145(5):1711-1725. doi: 10.1093/brain/awac064. Brain. 2022. PMID: 35661859 Free PMC article.
High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: the German-Austrian multicenter trial DAL-HD-90. The German-Austrian Pediatric Hodgkin's Disease Study Group.
Schellong G, Pötter R, Brämswig J, Wagner W, Prott FJ, Dörffel W, Körholz D, Mann G, Rath B, Reiter A, Weissbach G, Riepenhausen M, Thiemann M, Schwarze EW. Schellong G, et al. Among authors: riepenhausen m. J Clin Oncol. 1999 Dec;17(12):3736-44. doi: 10.1200/JCO.1999.17.12.3736. J Clin Oncol. 1999. PMID: 10577845 Clinical Trial.
[Reducing radiation dosage to 20-30 Gy in combined chemo-/radiotherapy of Hodgkin's disease in childhood. A report of the cooperative DAL-HD-87 therapy study].
Schellong G, Hörnig-Franz I, Rath B, Ritter J, Riepenhausen M, Kabisch H, Goldschmitt-Wuttge B, Schmidt P, Niethammer D, Gaedicke G, et al. Schellong G, et al. Among authors: riepenhausen m. Klin Padiatr. 1994 Jul-Aug;206(4):253-62. doi: 10.1055/s-2008-1046611. Klin Padiatr. 1994. PMID: 7967421 Clinical Trial. German.
Breast cancer in young women after treatment for Hodgkin's disease during childhood or adolescence--an observational study with up to 33-year follow-up.
Schellong G, Riepenhausen M, Ehlert K, Brämswig J, Dörffel W; German Working Group on the Long-Term Sequelae of Hodgkin's Disease; Schmutzler RK, Rhiem K, Bick U; German Consortium for Hereditary Breast and Ovarian Cancer. Schellong G, et al. Among authors: riepenhausen m. Dtsch Arztebl Int. 2014 Jan 6;111(1-2):3-9. doi: 10.3238/arztebl.2014.0003. Dtsch Arztebl Int. 2014. PMID: 24565270 Free PMC article.
15 results